Yogamet-GM 2 Forte Tablet is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. This dual mechanism addresses both insulin deficiency and insulin resistance, providing effective glycemic control. Yogamet-GM 2 Forte is typically prescribed when diet, exercise, and monotherapy with either agent alone do not achieve adequate blood sugar regulation. It is essential to monitor blood glucose levels regularly to adjust dosage and minimize the risk of hypoglycemia, particularly due to glimepiride’s insulinotropic effect. The medication should be used cautiously in patients with renal or hepatic impairment, and contraindications include severe renal dysfunction, metabolic acidosis, and hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and, rarely, lactic acidosis. Patients are advised to adhere to prescribed dietary and lifestyle modifications alongside therapy and consult healthcare providers for any unusual symptoms or concerns during treatment with Yogamet-GM 2 Forte Tablet.